

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/059133 A2

(51) International Patent Classification⁷: **C12N 15/11**,
A61K 31/7125, 31/04, 31/166, 31/52, 31/7048, A61P
35/00

93093 Donaustauf (DE). **SCHLINGENSIEPEN, Reimar**
[DE/DE]; Auf der Platte 4, 93051 Regensburg (DE).

(21) International Application Number:
PCT/EP2004/053604

(74) Agents: **SCHREIBER, Christoph et al.**; P.O. Box 10 22
41, 50462 Cologne (DE).

(22) International Filing Date:
20 December 2004 (20.12.2004)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03029367.4 19 December 2003 (19.12.2003) EP
60/541,771 5 February 2004 (05.02.2004) US

(71) Applicant (*for all designated States except US*): **ANTI-
SENSE PHARMA GMBH** [DE/DE]; Josef-Engert-Str. 9,
93053 Regensburg (DE).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SCHLINGEN-
SIEPEN, Karl-Hermann** [DE/DE]; Schubertstrasse 5,

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: PHARMACEUTICAL COMPOSITION



(57) Abstract: The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/ or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and/or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytostatic active antibiotics, caphtotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormon.



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*